Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy. // Journal of Cystic Fibrosis. – URL: https://www.sciencedirect.com/science/article/pii/S1569199326037410?dgcid=rss_sd_all
Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy. Journal of Cystic Fibrosis. https://www.sciencedirect.com/science/article/pii/S1569199326037410?dgcid=rss_sd_all
“Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy.” Journal of Cystic Fibrosis.
@article{article52888,
title = {Extrapulmonary benefits and pharmacogenomics in lung transplant recipients with Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy},
journal = {Journal of Cystic Fibrosis},
url = {https://www.sciencedirect.com/science/article/pii/S1569199326037410?dgcid=rss_sd_all}
}
ABSTRACT Aim To investigate the longitudinal association between early‐life movement behaviour patterns and later clinically diagnosed obesity. Method In the population‐based All Babies in Southeast Sweden (ABIS) cohort, 16 415 children...